461 related articles for article (PubMed ID: 30319248)
1. Current appraisal of single inhaler triple therapy in COPD.
Lipworth B; Kuo CR; Jabbal S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248
[TBL] [Abstract][Full Text] [Related]
2. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
4. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
5. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
6. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
[TBL] [Abstract][Full Text] [Related]
10. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
[TBL] [Abstract][Full Text] [Related]
11. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
[TBL] [Abstract][Full Text] [Related]
12. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
Bloom CI; Elkin SL; Quint JK
Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
[TBL] [Abstract][Full Text] [Related]
13. Stepwise management of COPD: What is next after bronchodilation?
Miravitlles M; Matsunaga K; Dreher M
Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
Tariq SM; Thomas EC
Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
[TBL] [Abstract][Full Text] [Related]
16. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
Suissa S; Dell'Aniello S; Ernst P
Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
[TBL] [Abstract][Full Text] [Related]
19. [Trimbow® : twice-daily triple combination for the treatment of COPD].
Corhay JL; Bonhomme O; Guiot J
Rev Med Liege; 2018 Sep; 73(9):480-484. PubMed ID: 30188035
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
Lee HW; Kim HJ; Jang EJ; Lee CH
Respiration; 2021; 100(7):631-643. PubMed ID: 33971649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]